Stuttgart
19.01.26 | 19:31
0,083 Euro
-3,28 % -0,003
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,083 | 0,098 | 19:47 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. | 1.046 | Business Wire | Q4 2025 revenue up 19% on a reported basis (+29% excluding currency effects CER) Sales in the United States up 65% (+82% at CER) after three consecutive quarters of acceleration (+11%, +23%,... ► Artikel lesen | |
| 09.01. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 246 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.12.25 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 345 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.12.25 | Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management | 393 | Business Wire | Integrating Cellvizio into TaeWoong's portfolio of therapeutic devices to create the first fully integrated "imaging-to-therapy" solution for EUS-guided pancreatic care
Regulatory News:
Mauna... ► Artikel lesen | |
| 20.11.25 | Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio Platform | 473 | Business Wire | NMPA approval obtained following a 3-year certification process Mauna Kea is now evaluating options to commercialize Cellvizio Gen 3 in China independently of the JV with Tasly
Regulatory... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 17.11.25 | XFRA 1MK: WIEDERAUFNAHME/RESUMPTION | 235 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14.11.25 | Mauna Kea Technologies: €6 Million Raised To Strengthen Long Term Growth | 2 | pulse2.com | ||
| 14.11.25 | Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise | 537 | Business Wire | 70% debt write-off, from €40M to €12M Remaining debt to be repaid over 10 years, with 90% between the end of 2029 and the end of 2035 Capital raise of €6.1M extending cash runway to the second... ► Artikel lesen | |
| 13.11.25 | XFRA 1MK: AUSSETZUNG/SUSPENSION | 485 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMAUNA KEA TECHNOL.EO... ► Artikel lesen | |
| 13.11.25 | Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise | 429 | Business Wire | Safeguard plan approved by judgment of the Paris Commercial Court on November 12, 2025 Launch of a reserved capital increase in the form of shares with attached warrants (ABSA) at a price of... ► Artikel lesen | |
| 06.11.25 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 325 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 21.10.25 | Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase | 459 | Business Wire | New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability The future exercise of share subscription warrants (BSA)... ► Artikel lesen | |
| 13.10.25 | Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates | 294 | Business Wire | U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year Commercial momentum highlighted by a doubling of U.S. system sales year-to-date Adding to U.S. commercial... ► Artikel lesen | |
| 08.10.25 | Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan | 593 | Business Wire | Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants (ABSA) Firm commitment from an investor for... ► Artikel lesen | |
| 06.10.25 | Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring | 966 | Business Wire | A large majority of creditors and shareholders have voted in favor of the draft safeguard plan This plan includes a 70% reduction in debt, from €40 million to €12 million, with a payment schedule... ► Artikel lesen | |
| 02.10.25 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 388 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 01.10.25 | Mauna Kea Technologies Announces 2025 Half-Year Results | 389 | Business Wire | 32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments Improvement Reflects Strict Expense Control and 17% U.S. Sales Growth1 Finalization of Safeguard Plan... ► Artikel lesen | |
| 22.09.25 | Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan | 448 | Business Wire | Reduction of the Company's debt from €40 million to €12 million, spread over 10 years Capital increase of at least €5 million post-plan adoption, with the issuance of stock warrants (BSAs) to... ► Artikel lesen | |
| 18.09.25 | Mauna Kea Technologies and Endotherapeutics Announce Cellvizio First Australian Orders, Advancing CellTolerance Commercial Expansion | 703 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today announced that Cellvizio system has been included in the Australian Register of Therapeutic Goods... ► Artikel lesen | |
| 12.09.25 | Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround | 731 | Business Wire | Shareholders, holders of securities giving access to the capital, and creditors of Mauna Kea Technologies convened into classes of affected parties to vote on the safeguard plan
Regulatory News:... ► Artikel lesen |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,097 | -0,51 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| FAMICORD | 5,750 | -0,86 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,740 | -4,86 % | Geratherm Medical AG: Kleine Investition erweitert Portfolio; KAUFEN bestätigt | Geratherm Medical erweitert sein Lifestyle- und Gesundheitsportfolio durch den Erwerb einer 27,5%-Beteiligung an dem in München ansässigen Startup oooxygen Health GmbH. Die Partnerschaft beginnt im... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,288 | +3,12 % | PLUS THERAPEUTICS, INC. - 8-K, Current Report | ||
| MEDICLIN | 3,880 | +2,11 % | EQS-News: MEDICLIN AG: Dr. Joachim Ramming verlässt den Vorstand der MEDICLIN AG zum Ende des Geschäftsjahres 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Personalie
Dr. Joachim Ramming verlässt den Vorstand der MEDICLIN AG zum Ende des Geschäftsjahres 2025
16.12.2025 / 15:00 CET/CEST
Für... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,547 | +2,63 % | Atossa Therapeutics Inc: Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy | Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation
SEATTLE... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc. - 8-K, Current Report | ||
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-K, Annual Report | ||
| VERU | 2,690 | +11,16 % | Veru Inc.: Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress | -- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an... ► Artikel lesen | |
| LIFEWARD | 0,690 | -4,48 % | Oramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic Transaction | Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD Technology) to Lifeward and Positions Oramed as a Significant Shareholder
Oramed will transfer... ► Artikel lesen | |
| LIGHT AI | 0,054 | -6,25 % | Light AI Inc: Light AI president, CTO Schaller resigns | ||
| MAVEN BRANDS | 0,001 | 0,00 % | Maven Brands Inc: Maven Brands to sell subdivided Lumby land for $3.5M | ||
| EKSO BIONICS | 8,860 | +3,63 % | Applied Digital Corporation: Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale | DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial... ► Artikel lesen | |
| VENUS CONCEPT | 7,940 | +455,24 % | Venus Concept Stock Explodes Over 500% After Major Investor Takes Control |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -3,28 % bei einem Aktienkurs von 0,083 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.